Furthermore, a recent phase II basket trial of dual blockade with ipilimumab (anti-CTLA4) and nivolumab (anti-PD1) in nonpancreatic neuroendocrine tumors showed an impressive 44% response rate (8 out of 18 patients) in high grade tumors versus 0% (0 out of 14 patients) in low or intermediate grade tumors [29]. The gene discussed is CTLA4; the disease is neuroendocrine neoplasm.